# Mesa Laboratories Inc: overview

MLAB · Nasdaq · CIK 724004 · [Technology](/sectors/technology.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/mlab.md) · [Financials](/companies/mlab/financials.md) · [Filings](/companies/mlab/filings.md) · [Insiders](/companies/mlab/insiders.md)

Latest reported revenue: [$60.1m](/filings/0001437749-26-026808.md) for Q1 FY2027, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-026808).

## Last eight quarters

| Line item | Unit | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [57.8](/filings/0000724004-25-000013.md) | [62.8](/filings/0000724004-26-000016.md) | [62.1 d](/filings/0000724004-26-000047.md) | [59.5](/filings/0001437749-26-026808.md) | [60.7](/filings/0000724004-25-000013.md) | [65.1](/filings/0000724004-26-000016.md) | [63.7 d](/filings/0000724004-26-000047.md) | [60.1](/filings/0001437749-26-026808.md) |
| Gross margin | % | [61.3%](/filings/0000724004-25-000013.md) | [63.3%](/filings/0000724004-26-000016.md) | [61.8% d](/filings/0000724004-26-000047.md) | [62.0%](/filings/0001437749-26-026808.md) | [61.5%](/filings/0000724004-25-000013.md) | [64.2%](/filings/0000724004-26-000016.md) | [66.2% d](/filings/0000724004-26-000047.md) | [64.9%](/filings/0001437749-26-026808.md) |
| Operating margin | % | [6.1%](/filings/0000724004-25-000013.md) | [9.2%](/filings/0000724004-26-000016.md) | [2.4% d](/filings/0000724004-26-000047.md) | [5.1%](/filings/0001437749-26-026808.md) | [7.8%](/filings/0000724004-25-000013.md) | [12.2%](/filings/0000724004-26-000016.md) | [4.3% d](/filings/0000724004-26-000047.md) | [11.7%](/filings/0001437749-26-026808.md) |
| Net margin | % | [5.9%](/filings/0000724004-26-000016.md) | [(2.7%)](/filings/0000724004-26-000016.md) | [(11.4%) d](/filings/0000724004-26-000047.md) | [8.0%](/filings/0001437749-26-026808.md) | [4.1%](/filings/0000724004-26-000016.md) | [5.6%](/filings/0000724004-26-000016.md) | [(6.5%) d](/filings/0000724004-26-000047.md) | [4.7%](/filings/0001437749-26-026808.md) |
| Diluted EPS | $ per share | [0.63](/filings/0000724004-25-000013.md) | [(0.31)](/filings/0000724004-26-000016.md) | not reported | [0.85](/filings/0001437749-26-026808.md) | [0.45](/filings/0000724004-25-000013.md) | [0.65](/filings/0000724004-26-000016.md) | not reported | [0.49](/filings/0001437749-26-026808.md) |
| Free cash flow | $m | [3.5 d](/filings/0000724004-25-000013.md) | [17.3 d](/filings/0000724004-26-000016.md) | [11.9 d](/filings/0000724004-26-000047.md) | [0.9](/filings/0001437749-26-026808.md) | [7.1 d](/filings/0000724004-25-000013.md) | [18.0 d](/filings/0000724004-26-000016.md) | [13.5 d](/filings/0000724004-26-000047.md) | [14.2](/filings/0001437749-26-026808.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [184](/filings/0001437749-24-021606.md) | [219](/filings/0001437749-25-018586.md) | [216](/filings/0000724004-26-000047.md) | [241](/filings/0000724004-26-000047.md) | [249](/filings/0000724004-26-000047.md) |
| Gross margin | % | [59.2%](/filings/0001437749-24-021606.md) | [61.0%](/filings/0001437749-25-018586.md) | [61.6%](/filings/0000724004-26-000047.md) | [62.6%](/filings/0000724004-26-000047.md) | [63.5%](/filings/0000724004-26-000047.md) |
| Operating margin | % | [2.6%](/filings/0001437749-24-021606.md) | [1.5%](/filings/0001437749-25-018586.md) | [(125.9%)](/filings/0000724004-26-000047.md) | [6.8%](/filings/0000724004-26-000047.md) | [7.4%](/filings/0000724004-26-000047.md) |
| Net margin | % | [1.0%](/filings/0001437749-24-021606.md) | [0.4%](/filings/0001437749-25-018586.md) | [(117.6%)](/filings/0000724004-26-000047.md) | [(0.8%)](/filings/0000724004-26-000047.md) | [2.7%](/filings/0000724004-26-000047.md) |
| Diluted EPS | $ per share | [0.35](/filings/0001437749-24-021606.md) | [0.17](/filings/0001437749-25-018586.md) | [(47.20)](/filings/0000724004-26-000047.md) | [(0.36)](/filings/0000724004-26-000047.md) | [1.21](/filings/0000724004-26-000047.md) |
| Free cash flow | $m | [34.8](/filings/0001437749-24-021606.md) | [23.4](/filings/0001437749-25-018586.md) | [41.6](/filings/0000724004-26-000047.md) | [42.6](/filings/0000724004-26-000047.md) | [39.6](/filings/0000724004-26-000047.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mlab/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Long Path Partners LP](/funds/1905112.md) | 2026-06-30 | $47.5m | 477,126 |  | Added +71,543 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $43.9m | 440,552 |  | Added +46,701 |
| [Boston Partners](/funds/1386060.md) | 2026-06-30 | $26.4m | 265,149 |  | Reduced −3,562 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $23.6m | 237,457 |  | Added +4,814 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $20.3m | 203,739 |  | Added +33,177 |
| [Ranger Investment Management, L.P.](/funds/1319691.md) | 2026-06-30 | $17.3m | 173,988 |  | Reduced −28,915 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $15.6m | 156,979 |  | Reduced −5,137 |
| [Diamond Hill Capital Management, LLC (Investment Advisor)](/funds/1217541.md) | 2026-06-30 | $15.5m | 155,771 |  | Added +469 |
| [RAYMOND JAMES FINANCIAL INC](/funds/720005.md) | 2026-06-30 | $14.9m | 149,937 |  | Added +27,026 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $14.8m | 148,395 |  | Added +23,765 |

## Recent filings

[All 1,103 filings](/companies/mlab/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-13 | 08:00 ET | [8-K](/filings/0001437749-26-032499.md) | 2.05 Exit or disposal costs; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-032499 |
| 2026-09-08 | 15:26 ET | [8-K](/filings/0001437749-26-029813.md) | 5.07 Shareholder vote results | 0001437749-26-029813 |
| 2026-08-10 | 17:17 ET | [10-Q](/filings/0001437749-26-026808.md) | Quarterly report, period 2026-06-30 | 0001437749-26-026808 |
| 2026-08-10 | 16:03 ET | [8-K](/filings/0001437749-26-026769.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-026769 |
| 2026-07-30 | 17:18 ET | [8-K](/filings/0000724004-26-000082.md) | 5.05 Item not in the standard list; 9.01 Financial statements and exhibits | 0000724004-26-000082 |
| 2026-07-22 | 14:55 ET | [DEF 14A](/filings/0000724004-26-000071.md) | Proxy statement, period 2026-09-08 | 0000724004-26-000071 |
| 2026-06-15 | 17:29 ET | [8-K](/filings/0000724004-26-000056.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000724004-26-000056 |
| 2026-06-03 | 18:19 ET | [10-K](/filings/0000724004-26-000047.md) | Annual report, period 2026-03-31 | 0000724004-26-000047 |
| 2026-05-27 | 08:00 ET | [8-K](/filings/0000724004-26-000039.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000724004-26-000039 |
| 2026-03-23 | 16:25 ET | [8-K](/filings/0000724004-26-000030.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000724004-26-000030 |

## Latest annual report

[Form 10-K for the fiscal year ended Mar 31, 2026](/filings/0000724004-26-000047.md), filed Jun 3, 2026.

## Forecast league

Q2 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/17d61f02-30e4-4920-92d9-f3cf188fb420)

## About the filer

- CIK: 724004
- Tickers: MLAB
- Exchange: Nasdaq
- SIC code: 3823 Industrial Instruments For Measurement, Display, and Control
- State of incorporation: CO
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 18:36 ET. No prices; not investment advice.